Patents by Inventor Deborah H. Charych

Deborah H. Charych has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200368321
    Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • Publication number: 20200317784
    Abstract: Provided herein are combination methods and compositions for cancer therapies. The combinations modify multiple arms of the immune system, including an innate immunity modifier, an immune checkpoint inhibitor and a T-cell stimulator, to treat cancer.
    Type: Application
    Filed: November 13, 2018
    Publication date: October 8, 2020
    Inventors: Krishnan NANDABALAN, Vimal D. MEHTA, Luca RASTELLI, John MACDOUGALL, Jonathan ZALEVSKY, Deborah H. CHARYCH
  • Patent number: 10786552
    Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 29, 2020
    Assignee: Nektar Therapeutics
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • Publication number: 20200237747
    Abstract: The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.
    Type: Application
    Filed: April 15, 2020
    Publication date: July 30, 2020
    Inventors: Ute Hoch, Nancy Marie Burns, Deborah H. Charych
  • Patent number: 10653689
    Abstract: The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: May 19, 2020
    Assignee: Nektar Therapeutics
    Inventors: Ute Hoch, Nancy Marie Burns, Deborah H. Charych
  • Publication number: 20200016206
    Abstract: Provided are methods and compositions directed towards the treatment of an individual having cancer by providing adoptive cell transfer therapy and administering to the individual a long acting IL-2R??-biased agonist.
    Type: Application
    Filed: March 1, 2018
    Publication date: January 16, 2020
    Inventors: Deborah H. Charych, Antoni Ribas, Giulia Parisi
  • Publication number: 20190290733
    Abstract: Conjugates of an IL-7 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the non-peptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to an individual.
    Type: Application
    Filed: March 11, 2016
    Publication date: September 26, 2019
    Inventors: Deborah H. Charych, Ping Zhang, Peter Benedict Kirk
  • Publication number: 20190275133
    Abstract: Provided herein are methods and compositions for treating a subject having cancer by administering to the subject a cancer vaccine accompanied by administration of a long acting IL-2R??-biased agonist.
    Type: Application
    Filed: November 9, 2017
    Publication date: September 12, 2019
    Inventors: Deborah H. Charych, Jonathan Zalevsky, Willem Overwijk, Meenu Sharma, Adi Diab, Patrick Hwu
  • Publication number: 20190030182
    Abstract: Compounds comprising a binding moiety, water-soluble, non-peptidic polymer, and drug are provided. Also provided are methods preparing such compounds, compositions comprising such compounds and methods for administering and using such compounds and compositions.
    Type: Application
    Filed: October 2, 2018
    Publication date: January 31, 2019
    Inventors: Jennifer Riggs-Sauthier, Deborah H. Charych, Clark Norman Eid, JR., Dennis G. Fry, Marina Konakova, Christine Frances Loehrlein
  • Publication number: 20180344810
    Abstract: The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 6, 2018
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • Publication number: 20180296645
    Abstract: In one or more embodiments of the invention, a method is provided, the method comprising the steps of administering to a cancer patient: (a) an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and (b) an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a composition is provided, the composition comprising: an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; and an IL-15R-activating amount of a long-acting, IL-15 moiety. In one or more embodiments of the invention, a kit is provided, the kit comprising: an IL-2R?-activating amount of a long-acting, IL-2R?-selective agonist; an IL-15R-activating amount of a long-acting, IL-15 moiety; and instructions for use of the IL-2R?-selective agonist and the long-acting, IL-15 moiety.
    Type: Application
    Filed: October 7, 2016
    Publication date: October 18, 2018
    Inventors: Deborah H. Charych, Peter Benedict Kirk
  • Patent number: 10010587
    Abstract: The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: July 3, 2018
    Assignee: Nektar Therapeutics
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • Publication number: 20180085468
    Abstract: Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the non-peptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.
    Type: Application
    Filed: December 7, 2017
    Publication date: March 29, 2018
    Inventors: Mary J. Bossard, Cherie F. Ali, Xiaofeng Liu, Deborah H. Charych, Harold Zappe, Yujun Wang, Jicai Huang
  • Patent number: 9861705
    Abstract: Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: January 9, 2018
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Cherie F. Ali, Xiaofeng Liu, Deborah H. Charych, Yujun Wang
  • Publication number: 20170128539
    Abstract: The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.
    Type: Application
    Filed: February 20, 2015
    Publication date: May 11, 2017
    Inventors: Murali Krishna Addepalli, Deborah H. Charych, Seema Kantak, Steven Robert Lee
  • Publication number: 20170035898
    Abstract: Conjugates of an IL-15 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to an individual.
    Type: Application
    Filed: April 1, 2015
    Publication date: February 9, 2017
    Inventors: Xiaofeng Liu, Peter Benedict Kirk, Thomas Chang, Deborah H. Charych
  • Publication number: 20160339013
    Abstract: The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.
    Type: Application
    Filed: January 13, 2015
    Publication date: November 24, 2016
    Inventors: Ute Hoch, Nancy Marie Burns, Deborah H. Charych
  • Patent number: 9175065
    Abstract: Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: November 3, 2015
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Shannon Marshall, Deborah H. Charych, Ali Sadra
  • Publication number: 20140328791
    Abstract: Conjugates of an IL-2 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.
    Type: Application
    Filed: November 11, 2011
    Publication date: November 6, 2014
    Inventors: Mary J. Bossard, Cherie F. Ali, Xiaofeng Liu, Deborah H. Charych, Harold Zappe, Yujun Wang, Jicai Huang
  • Publication number: 20140088021
    Abstract: Compounds comprising a binding moiety, water-soluble, non-peptidic polymer, and drug are provided. Also provided are methods preparing such compounds, compositions comprising such compounds and methods for administering and using such compounds and compositions.
    Type: Application
    Filed: May 24, 2012
    Publication date: March 27, 2014
    Applicant: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Deborah H. Charych, Clark Norman Eid, Dennis G. Fry, Marina Konakova, Christine Frances Loehrlein